[Importance of recombinant proteins in the adjuvant treatment of cancer].
The clinical application of hematopoietic growth factors, which decrease the duration (and severity) of chemotherapy-induced myelosuppression, was made possible by using genetically-modified micro-organisms to produce them (e.g. epoietin). The interest of these products is double: in attenuating the myelosuppression, they decrease the risk of severe infectious complications; the better hematologic tolerance allows to deliver chemotherapy in higher doses that maximize tumoricidal activity.
Cheron
J M
JM
Hôpital Sainte-Périne, Paris.
D017024:Chemotherapy, Adjuvant; D016298:Hematopoietic Cell Growth Factors / Q000627:therapeutic use*; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D011994:Recombinant Proteins / Q000627:therapeutic use
D016298:Hematopoietic Cell Growth Factors; D011994:Recombinant Proteins
Intérêt des protéines recombinées dans le traitement adjuvant des cancers.